CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 114 enrolled
Drug / intervention
Naltrexone Injectable Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03275350
NCT03275350Phase 3Completed
CompareCT.gov

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

Oregon Health and Science University·interventional·Posted Sep 7, 2017·Updated Apr 27, 2022

In Brief

A Phase 3 clinical trial evaluating Naltrexone Injectable Suspension and Treatment as usual for Opioid-use Disorder and Hiv. Completed, enrolled 114 participants across 5 sites.

Detailed Summary

The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder, Hiv
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Johns Hopkins University, University of Kentucky, Jackson Health System, Tarzana Treatment Centers, Ruth M. Rothstein CORE Center

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 7, 2017
Enrollment StartFeb 5, 2018
Primary CompletionNov 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.8 years ago

Interventions

Naltrexone Injectable Suspensiondrug

Six monthly injections of extended-release naltrexone

Treatment as usualother

Standard treatment for opioid use disorder provided at each HIV clinic